drugset / Trial / NCT02621489

Effects on Re-endothelialisation With Bydureon Treatment in Type 2 Diabetes Subjects

NCT02621489 ↗

Phase 4 Completed 38 enrolled Karolinska Institutet
RandomizedParallel-groupOpen-labelTreatment

Summary

The aim of the study is to use Exenatide long-acting release (LAR) \[Bydureon\] to minimize vascular remodeling and neointima formation after Percutaneous Coronary Intervention (PCI) and to accelerate stent endothelialisation.

Timeline

Start
2015-12
Primary completion
2022-08
Completion
2022-10

Outcome

Missed primary endpoint

paper Twelve weeks treatment with exenatide did not lead to a significantly better stent coverage in people with T2D. PMID 38066597 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Exenatide Peptide 2 mg Subcutaneous
Background Humulin kwickpen Unknown 10 iu Subcutaneous
Background Metformin Small molecule 1 g —